Bpifrance

Vaxinano is a biotechnology company focused on the preclinical and pharmaceutical development of vaccines and drug delivery systems for both humans and animals. Established in 2016, Vaxinano builds on 25 years of research and clinical trials related to vaccines, utilizing the patented technology of Pr Didier Betbeder. The company specializes in creating safe-by-design nanoparticles that adhere to green chemistry principles, which support the development of prophylactic and therapeutic vaccines for infectious diseases. Additionally, Vaxinano aids medical researchers in formulating drugs that activate biomolecules, proteins, and antigens, thereby facilitating innovative approaches to combat untreated viral, bacterial, and parasitic diseases.

Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (Cyril Rivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.

SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules.

AQEMIA is a pharmatech company focused on drug discovery, utilizing a platform that integrates machine learning with quantum-inspired physics. This innovative approach allows for the efficient identification of new drug candidates aimed at specific therapeutic targets. By employing advanced algorithms, AQEMIA's platform is capable of predicting the interactions and affinities between potential drug molecules and their targets. This methodology not only accelerates the drug discovery process but also contributes to a growing pipeline of viable drug candidates for various medical applications.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Quobly specializes in the development and marketing of a universal large-scale quantum computer, leveraging established semiconductor industry techniques. The company focuses on creating quantum computing semiconductors designed for commercial applications, enabling clients to utilize quantum computers for various complex problems. These applications include optimizing energy distribution and accelerating drug development by computing chemical properties more efficiently. Quobly aims to meet the specific needs of its clients by providing reliable and effective quantum computing solutions based on proven semiconductor processes.

Kairos Discovery is a biotechnology company focused on developing innovative targeted cancer therapies. The company aims to create medicinal chemistry solutions that address key cellular mechanisms responsible for the survival and aggressiveness of both solid tumors and hematological cancers. By utilizing a first-in-class approach, Kairos Discovery seeks to provide breakthrough technology in oncology, ultimately improving the lives of cancer patients and their families.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Odimma is a biotech company that focuses on precision medicine and cure for personalized cancer immunotherapy.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and decentralized clinical trial solutions, dedicated to enhancing data collection processes in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has developed expertise in eCOA solutions applicable across all phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. To meet the evolving demands of clinical research, Kayentis offers a comprehensive suite of services that prioritize scientific integrity and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, the company's technology facilitates electronic data capture, providing a versatile range of tools designed to simplify data collection for both patients and clinical trial sites.

AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

Jalon Therapeutics is focused on developing innovative therapies that target essential tumor signaling pathways that have not yet been addressed. The company aims to transform the lives of cancer patients by creating medicines that effectively inhibit these pathways. Through its research, Jalon Therapeutics explores the potential of non-oncogene addiction to discover new therapeutic targets and develop groundbreaking anticancer treatment strategies. The company's work is centered on improving treatment options for individuals battling cancer, ultimately striving to enhance their quality of life.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is centered around its lead product, Glunozumab, a monoclonal antibody that operates through a unique mechanism of action. This drug induces off-target toxicity by hyperactivating vascular and neuronal NMDA receptors, which can lead to significant disruptions in the blood-brain and blood-spinal cord barriers, as well as neuronal excitotoxicity. These effects are particularly relevant in conditions such as stroke and multiple sclerosis, where the modulation of neuroinflammation is critical for treatment.

Valneva is a pharmaceutical company specializing in the development of prophylactic vaccines aimed at addressing infectious diseases with significant unmet medical needs. The company has successfully commercialized several vaccines, including IXIARO/JESPECT, DUKORAL, and IXCHIQ, primarily targeting travelers. In addition to its marketed products, Valneva is advancing a diverse pipeline of vaccine candidates, including those for Lyme disease, chikungunya, and COVID-19. The company is involved in the entire lifecycle of vaccine development, encompassing research, manufacturing, and distribution. Valneva also offers technologies and services aimed at enhancing vaccine commercialization, which further supports its mission to deliver life-saving immunizations globally.

Guerbet is a human-scale company that aims to become a new global leader in medical imaging. Pioneer in contrast media with 90 years'​ experience, Guerbet is the only pharmaceutical group dedicated to medical imaging worldwide, with a presence in almost 80 countries via a network of subsidiaries and distributors. The company offers a comprehensive range of CT scan, Cath Lab, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostic (IRT) products, along with a range of injectors and related medical devices to improve patients'​ diagnosis, prognosis and quality of life.

Apmonia Therapeutics developing a pipeline of next generation peptide based therapies targeting the tumor microenvironment to improve the lives of patients with cancer. If anyone would want to contact them please contact them via phone call or email.

DeepLife is a biotech company based in Paris, France, founded in 2019. It focuses on developing digital twins of cells to enhance drug discovery processes. By utilizing deep learning techniques on multi-omics data, DeepLife models cellular behavior and simulates responses to various genetic screenings, such as siRNA and CRISPR-Cas9. This approach allows the identification of new drug targets, biomarkers, and potential drug candidates, enabling a better understanding of drug resistance and sensitivity. The company's mission is to advance systems biology and facilitate the transition of laboratory discoveries to clinical applications. DeepLife collaborates with academic institutions to leverage expertise and drive innovation in the biopharmaceutical industry, ultimately aiming to match the right drug to the right patient.

Qairn specializes in digitizing regulatory processes for healthcare manufacturers, including laboratories, medical devices, and biotechs. The company offers a SaaS platform that streamlines and secures mandatory procedures, facilitating the management of promotional materials and other regulated content. Qairn's services include the review and validation of promotional documents, submission to ANSM, and compliance support, allowing clients to efficiently navigate regulatory requirements while minimizing risks. By simplifying these processes, Qairn enables its clients to focus on innovation and improving healthcare outcomes.

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Priothera Ltd is a clinical-stage company based in Dublin, Ireland, with an additional location in Saint Louis, France. It specializes in the development of orally applied sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's primary focus is on its lead product, mocravimod, which is designed to enhance the curative potential of allogeneic haematopoietic stem cell transplants. By reducing the egress of T cell subsets from lymphatic tissues, Priothera's modulators aim to provide dual inhibition of graft versus host disease while also promoting graft versus leukemia effects, ultimately improving patient outcomes in this challenging area of medicine.

Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment.

SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.

MedinCell is an injectable slow-release drug specialist company.

Perha Pharmaceuticals is a biotechnology company that specializes in the research and development of kinase inhibitors. The company's investigation begins with natural marine substances. Indeed, some of the molecules optimized by Perha Pharmaceuticals' chemists and biologists are derived from natural products isolated from marine organisms.

Egle Therapeutics SAS is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing innovative immunotherapies that target immune suppressor regulatory T-cells (Tregs) for the treatment of oncology and autoimmune diseases. The company's research focuses on a proprietary drug pipeline that includes computationally designed IL-2 variants aimed at modulating Treg activity. This approach seeks to either engage or dis-engage Tregs, facilitating the development of therapies that can effectively combat cancer and other related conditions by addressing the immune suppression caused by Tregs. Egle Therapeutics aims to advance its unique portfolio to provide new treatment options in the healthcare field.

Provepharm Life Solutions SA is a life sciences company based in Marseille, France, specializing in contract research and development services for small molecules and therapeutic peptides. Founded in 1998, the company focuses on the development, manufacturing, and marketing of pharmaceutical products and active ingredients. A key offering is pharmacopoeial grade methylene blue, a versatile compound utilized in various human health applications, including as an antidote for methemoglobinemia, a mild urinary antiseptic, and a topical antiseptic. The company also addresses animal health needs, providing solutions for toxicosis and aquaculture. Methylene blue serves additional roles as a laboratory dye, indicator, and diagnostic aid in surgical procedures. Provepharm Life Solutions aims to lead in the life sciences sector through its innovative approach, known as Molecule Vitalization, and offers a range of research and manufacturing services to advance health solutions.

Inotrem S.A. is a biotechnology company that specializes in immunotherapy aimed at managing acute and chronic inflammatory syndromes. The company focuses on the TREM-1 pathway to regulate excessive inflammatory responses, utilizing its proprietary technology platform. Inotrem has developed a first-in-class TREM-1 inhibitor known as nangibotide (LR12), which shows promise in treating conditions such as septic shock and myocardial infarction. In addition to its acute inflammatory initiatives, Inotrem is also advancing a program targeting chronic inflammatory diseases, thereby expanding its therapeutic scope. Through its innovative approach, Inotrem aims to enhance treatment options for critical care patients facing a variety of inflammatory challenges.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

AQEMIA is a pharmatech company focused on drug discovery, utilizing a platform that integrates machine learning with quantum-inspired physics. This innovative approach allows for the efficient identification of new drug candidates aimed at specific therapeutic targets. By employing advanced algorithms, AQEMIA's platform is capable of predicting the interactions and affinities between potential drug molecules and their targets. This methodology not only accelerates the drug discovery process but also contributes to a growing pipeline of viable drug candidates for various medical applications.

Biophytis SA is a clinical-stage biotechnology company based in Paris, France, dedicated to developing therapeutics that aim to slow degenerative processes linked to aging and enhance functional outcomes for patients with age-related diseases. The company focuses on activating key biological resilience pathways to mitigate the effects of various biological and environmental stresses that contribute to these conditions. Biophytis has two primary drug candidates: Sarconeos (BIO101), an orally administered small molecule being developed for neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, and Macuneos (BIO201), also an orally administered small molecule targeting retinal diseases like dry age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon for the development of Sarconeos. Founded in 2006, Biophytis aims to become a leader in aging science by providing innovative therapies to address the needs of patients with limited treatment options.

Biophytis SA is a clinical-stage biotechnology company based in Paris, France, dedicated to developing therapeutics that aim to slow degenerative processes linked to aging and enhance functional outcomes for patients with age-related diseases. The company focuses on activating key biological resilience pathways to mitigate the effects of various biological and environmental stresses that contribute to these conditions. Biophytis has two primary drug candidates: Sarconeos (BIO101), an orally administered small molecule being developed for neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, and Macuneos (BIO201), also an orally administered small molecule targeting retinal diseases like dry age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon for the development of Sarconeos. Founded in 2006, Biophytis aims to become a leader in aging science by providing innovative therapies to address the needs of patients with limited treatment options.

Olgram is a biotechnology company that develops marine molecules for the prevention and control of chronic bacterial infections.Olgram has an original positioning to address this critical need by developing new products that will target, for the first time, dormant bacteria (responsible for infectious relapses) with a new class of anti-infectious.

Step Pharma, established in 2014 and based in Paris, France, focuses on developing innovative small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off from the Imagine Institute, the company leverages research on genetic immunodeficiencies conducted by Pr. Alain Fischer. Step Pharma operates as a joint venture with contributions from Imagine, Sygnature Discovery, and Kurma Partners, combining expertise in drug discovery and funding within the healthcare and biotechnology sectors. The company's proprietary therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This targeted approach enables selective modulation of immune cell populations, such as T and B cells, leading to enhanced treatment efficacy and improved therapeutic outcomes for patients with autoimmune conditions.

Seekyo is a privately-owned biotech company focused on developing advanced chemotherapies that specifically target the microenvironment of solid tumors. Its innovative approach aims to deliver potent anticancer agents while minimizing harm to healthy tissues, thereby reducing adverse effects for cancer patients. The company's "smart drugs" are designed to selectively transport these agents, utilizing a targeting unit for effective recognition of malignant cells. Additionally, Seekyo's technology incorporates a versatile enzyme-responsive self-immolative linker that enables controlled drug release exclusively at the tumor site. This targeted methodology seeks to enhance the efficacy and safety of cancer treatments, offering patients a more tolerable therapeutic option.

Iktos is a French company focused on artificial intelligence and robotic solutions for medicinal chemistry and drug design. It offers a proprietary generative AI technology that optimizes molecule design for small molecule discovery projects, significantly enhancing productivity in pharmaceutical research and development. Iktos provides its innovative solutions through its SaaS platforms, Makya™ for generative drug design and Spaya™ for retrosynthesis, while also engaging in strategic partnerships with pharmaceutical companies to accelerate drug discovery. Additionally, Iktos has developed an AI-driven synthesis automation platform, Iktos Robotics, which expedites the Design-Make-Test-Analyze cycle in drug development. The company is also advancing its own pipeline of drug candidates aimed at oncology and autoimmune diseases. In March 2023, Iktos secured a significant financing round, and in July 2024, it enhanced its capabilities by acquiring Synsight, which adds a biology platform for discovering drugs targeting Protein-Protein and RNA-Protein interactions.

NovAliX is a research organization specializing in drug discovery and pharmaceutical development. It provides a range of integrated services designed to address the outsourcing needs of the pharmaceutical industry, from initial discovery through to manufacturing. Utilizing proprietary technologies such as surface plasmon resonance (SPR), X-ray protein crystallography, and advanced NMR techniques, NovAliX offers comprehensive support for small molecule drug discovery and biologics characterization. The company's collaborative approach enables clients to access a unique combination of screening, medicinal chemistry, and structural biology, facilitating the development of effective drugs. Additionally, NovAliX conducts thorough analyses of active pharmaceutical ingredients (APIs) and polymorphism studies, supporting pharmaceutical development and manufacturing teams in their efforts to bring new therapies to market.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and decentralized clinical trial solutions, dedicated to enhancing data collection processes in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has developed expertise in eCOA solutions applicable across all phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. To meet the evolving demands of clinical research, Kayentis offers a comprehensive suite of services that prioritize scientific integrity and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, the company's technology facilitates electronic data capture, providing a versatile range of tools designed to simplify data collection for both patients and clinical trial sites.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Advicenne is a late-stage biopharmaceutical company founded in 2007 and headquartered in Nîmes, France. The company focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly targeting orphan renal diseases and niche neurology indications. Its lead drug candidate, ADV7103, is undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the lives of patients from early childhood through adulthood.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

ABC Transfer is a biopharmaceutical company that develops Rapid Transfer Systems (RTS) solutions.

SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company is advancing its lead product, DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 to treat Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is developing a complementary research portfolio that targets various other orphan disorders, including a program focused on hereditary spastic paraplegias linked to specific genetic mutations. Through its innovative approach and expertise in rare disease drug development, Dynacure seeks to address significant unmet medical needs in this underserved patient population.

Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

Fab'entech, founded in 2009 in Lyon, France, is a biopharmaceutical company that specializes in developing and commercializing innovative passive immunotherapeutic solutions. The company focuses on specific polyclonal immunoglobulins [F(ab’)₂] to address emerging infectious diseases and certain drug intoxications. By utilizing highly purified fragments of horse-specific polyclonal immunoglobulins, Fab'entech provides healthcare institutions with effective treatments for emergency situations. As a member of the LyonBiopôle cluster, the company is positioned within a network that fosters biotechnological advancements in the region.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasive procedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability. They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in developing innovative treatments for severe rare diseases with significant unmet medical needs. Its primary product candidate, Apraglutide, is a long-acting synthetic analog of glucagon-like peptide-2 (GLP-2) designed to enhance the intestine's ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support. VectivBio aims to deliver transformational therapies that significantly improve the lives of patients and their families, rather than offering only incremental benefits over existing treatments.

ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

NH TherAguix SAS is a clinical stage pharmaceutical company based in Villeurbanne, France, focused on developing nanomedicines for cancer treatment, specifically utilizing radiotherapy. The company's lead product, AGuIX, is a theranostic nanoparticle designed to enhance the localization of solid tumors and improve the effectiveness of radiation therapy. AGuIX allows for the determination of optimal irradiation timing and is capable of treating radioresistant cancers while minimizing radiation exposure to healthy tissues, thereby reducing secondary effects. Founded in 2015, NH TherAguix is dedicated to advancing innovative solutions in cancer care through its pioneering research and development efforts.

Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

Igyxos S.A. is a French company based in Nouzilly that focuses on developing pharmaceuticals and medical technologies aimed at enhancing human fertility. Established in 2017, Igyxos engages in all stages of drug development, beginning with the discovery of promising targets and progressing to the identification of lead compounds, including small molecules and monoclonal antibodies. The company specializes in developing solutions that improve the efficacy of gonadotropins and hormones critical for reproduction. Igyxos also facilitates the transition of potential drug candidates through pre-clinical and clinical phases, aiming to address the increasing global demand for effective infertility treatments for both men and women.

Alkion BioInnovations, established in March 2017, focuses on developing innovative cannabinoid and pharmaceutical active pharmaceutical ingredient (API) production through large-scale plant tissue culture. The company utilizes proprietary semi-industrial technologies to produce natural plant active ingredients for pharmaceutical applications, aiming to create disruptive nutrition, non-cosmetic oil, and agrochemical products for both the pharmaceutical and agri-food sectors. In addition to its work in cannabinoid production, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received multiple R&D grants and awards, including those from I-lab, I-Nov, and the European Innovation Council, recognizing its contributions to biotechnology and innovation.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Step Pharma, established in 2014 and based in Paris, France, focuses on developing innovative small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off from the Imagine Institute, the company leverages research on genetic immunodeficiencies conducted by Pr. Alain Fischer. Step Pharma operates as a joint venture with contributions from Imagine, Sygnature Discovery, and Kurma Partners, combining expertise in drug discovery and funding within the healthcare and biotechnology sectors. The company's proprietary therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This targeted approach enables selective modulation of immune cell populations, such as T and B cells, leading to enhanced treatment efficacy and improved therapeutic outcomes for patients with autoimmune conditions.

ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

Advicenne is a late-stage biopharmaceutical company founded in 2007 and headquartered in Nîmes, France. The company focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly targeting orphan renal diseases and niche neurology indications. Its lead drug candidate, ADV7103, is undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the lives of patients from early childhood through adulthood.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Alkion BioInnovations, established in March 2017, focuses on developing innovative cannabinoid and pharmaceutical active pharmaceutical ingredient (API) production through large-scale plant tissue culture. The company utilizes proprietary semi-industrial technologies to produce natural plant active ingredients for pharmaceutical applications, aiming to create disruptive nutrition, non-cosmetic oil, and agrochemical products for both the pharmaceutical and agri-food sectors. In addition to its work in cannabinoid production, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received multiple R&D grants and awards, including those from I-lab, I-Nov, and the European Innovation Council, recognizing its contributions to biotechnology and innovation.

MedDay is an international pioneering fully integrated biopharmaceutical company. At MedDay, they believe that it is possible to treat neurodegenerative diseases by targeting key neurometabolic pathways. They strive to develop neuro repair disease modifying therapies and to provide solutions to patients, their caregivers and the healthcare community, in order to improve patient care in areas of high unmet medical need. Promising clinical trial outcomes have encouraged us to date, and are continuing to drive us to pursue this direction. In daring to explore disrupted metabolic pathways in the central nervous system, their teams push the limits to improve future treatment options for patients suffering from neurodegenerative diseases.

Theravectys is a biotechnology company focused on developing a novel vaccine platform aimed at treating and preventing a wide array of infectious diseases, cancers, and other medical conditions. The company’s innovative vaccination technology utilizes gene transfer into dendritic cells to modulate the immune response, enhancing the effectiveness of both prophylactic and therapeutic immunotherapies. Their lead product, a therapeutic vaccine targeting HIV/AIDS, has demonstrated promising efficacy and safety in non-human primate studies and is set to enter clinical trials. Through its diverse pipeline, Theravectys aims to provide healthcare providers with advanced treatment options that elicit a potent and targeted immune response in patients.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Skuldtech is specialized in the discovery of new Biomarkers and the development of Diagnostics focused on personalized medicine applications. This expertise enables the company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics associated with new treatments, especially in cancer, neurodegenerative and infectious diseases.

Nanobiotix SA develops nanomedicine programs for the treatment of cancer. The company provides NanoXray that offers a solution for cancer therapy based on a technology that is designed to allow destruction of cancer cells by inert particles. Its products include magnetic particles and laser activated nanoparticles for the treatment and diagnostic of cancer.

Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell lymphoma; Livatag, a nanoparticle formulation of doxorubicin, which is in Phase III clinical trials for the treatment of primary liver cancer; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trials for the prevention and the treatment of chemoradioation therapy-induced severe oral mucositis in patients with head and neck cancer; and Combo BelCHOP, which is Phase II clinical trials for the treatment of peripheral T-cell lymphoma. Onxeo is headquartered in Paris, France.

Nanobiotix SA develops nanomedicine programs for the treatment of cancer. The company provides NanoXray that offers a solution for cancer therapy based on a technology that is designed to allow destruction of cancer cells by inert particles. Its products include magnetic particles and laser activated nanoparticles for the treatment and diagnostic of cancer.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Nanobiotix SA develops nanomedicine programs for the treatment of cancer. The company provides NanoXray that offers a solution for cancer therapy based on a technology that is designed to allow destruction of cancer cells by inert particles. Its products include magnetic particles and laser activated nanoparticles for the treatment and diagnostic of cancer.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.